Predicting Outcome of Therapeutic Lymphadenectomy in Late-Stage Melanoma
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Predicting Outcome of Therapeutic Lymphadenectomy in Late-Stage Melanoma

› Forums › General Melanoma Community › Predicting Outcome of Therapeutic Lymphadenectomy in Late-Stage Melanoma

  • This topic is empty.
  • Post
    • March 28, 2014 at 12:51 pm
    lou2
    Participant

      Nomograms Can Predict Outcome of Therapeutic Lymphadenectomy in Late-Stage Melanoma

       

      Research · March 10, 2014
       
       

      TAKE-HOME MESSAGE

      • In this study, a mathematical model was developed to predict the response of patients diagnosed with stage IIIB and IIIC melanoma to therapeutic lymph node dissection. Extracapsular extension and nodular pathology subtypes were good predictors for 2-year recurrence incidence. Age, number of positive lymph nodes, and extracapsular extension were predictors for overall survival. 
      • This mathematical model provides assistance in predicting outcomes in patients with late-stage melanoma and clinically involved lymph nodes.

      – Chris Tully, MD

       

      ABSTRACT

      The publisher has made this article available for free until 4/9/2014 12:00:00 AM .

      Access this article now

      Background

      Current staging algorithms in melanoma patients undergoing therapeutic lymph node dissection (LND) fail to accurately distinguish long-term survivors from those at risk of rapid relapse. Our goal was to establish and validate nomograms for predicting both recurrence and survival after LND.

      Methods

      A prospective cohort of stage IIIB and IIIC melanoma patients was ascertained from a tertiary hospital in Brisbane, Australia. Failure-time multivariate analysis identified key factors that, in adjusted combinations, generated nomograms to predict 2-year recurrence and 5-year melanoma-specific survival. The predictive value of these nomograms was further validated in a patient cohort from Rotterdam, The Netherlands.

      Results

      In 494 Australian patients, number of positive lymph nodes, extra-capsular extension and nodular histopathological subtype were the main independent predictors of 2-year recurrence while age, number of positive nodes and extra-capsular extension were the independent predictors of survival. Predictive value was confirmed in The Netherlands cohort of 331 patients. The nomograms were able to classify patients according to their 2-year recurrence and 5-year survival rates even within each stage III sub-class.

      Conclusions

      Models that include extra-capsular extension predict outcomes in patients with clinically involved lymph nodes. This tool may help tailor treatment and monitoring of this group of patients.

      European Journal of Cancer

      Nomograms to Predict Recurrence and Survival in Stage IIIB and IIIC Melanoma After Therapeutic Lymphadenectomy

      Eur. J. Cancer 2014 Mar 10;[EPub Ahead of Print], K Khosrotehrani

      Copyright © 2014 Elsevier Inc. All rights reserved.

       

    Tagged: 

    • You must be logged in to reply to this topic.
    About the MRF Patient Forum

    The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

    The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.